Abstracts tagged "interstitial lung disease"

Abstract Number: 2912 • 2016 ACR/ARHP Annual Meeting
Performance of the Patient-Reported Outcomes Measurement Information System (PROMIS) 29 in Systemic Sclerosis -Associated Interstitial Lung Disease (SSc-ILD)
Caitlyn Fisher^1,2, Rajaie Namas³, Amber Young², Holly Wilhalme⁴ and Dinesh Khanna⁵, ¹Cognitive Science / Creative Writing, Beloit College, Beloit, WI, ²Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, ³Department of Medicine [Division of Rheumatology], University of Michigan, Ann Arbor, MI, ⁴University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁵University of Michigan, Ann Arbor, MI
Background/Purpose: PROMIS-29 is a generic health-related quality of life (HRQoL) instrument that was developed as part of the NIH Patient Reported Outcomes (PROs) Roadmap. Our…
Abstract Number: 971 • 2016 ACR/ARHP Annual Meeting
Reliability and Minimal Clinically Important Differences (MCID) of Forced Vital Capacity: Post-Hoc Analyses from the Scleroderma Lung Studies (SLS-I and II)
Suzanne Kafaja¹, Philip J. Clements², Holly Wilhalme³, Daniel E. Furst⁴, Chi-hong Tseng², Kim Hyun⁵, Jonathan Goldin³, Elizabeth R. Volkmann³, Michael Roth², Donald P. Tashkin⁶ and Dinesh Khanna⁷, ¹Medicine/Rheumatology, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ³University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁵Radiology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, ⁶David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, ⁷University of Michigan, Ann Arbor, MI
Background/Purpose: Forced vital capacity (FVC) is used as a primary outcome measure in clinical trials of systemic sclerosis-related interstitial lung disease (SSc-ILD). Minimally Clinically Important…
Abstract Number: 3249 • 2016 ACR/ARHP Annual Meeting
Improvement in Cough and Cough-Related Quality of Life in Participants Undergoing Treatment for Systemic Sclerosis-Related Interstitial Lung Disease
Elizabeth R. Volkmann¹, Dinesh Khanna², Chi-hong Tseng³, Robert Elashoff⁴, Bingling Wang⁵, Michael Roth³, Philip J. Clements³, Daniel E. Furst¹, Arthur Theodore⁶ and Donald P. Tashkin⁷, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²University of Michigan, Ann Arbor, MI, ³Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴Biomathematics, University of California, Los Angeles, Los Angeles, CA, ⁵Biostatistics, University of California, Los Angeles, Los Angeles, CA, ⁶Medicine, Boston University, Boston, MA, ⁷David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA
Background/Purpose: While chronic cough occurs in the majority of patients with systemic sclerosis-related interstitial lung disease (SSc-ILD),1 its impact on quality of life has not…
Abstract Number: 1236 • 2016 ACR/ARHP Annual Meeting
Rheumatoid Arthritis-Interstitial Lung Disease in the United States: Prevalence, Incidence, and Healthcare Costs
Karina Raimundo¹, Amanda Farr², Ashley Cole³ and Jeffrey J. Swigris⁴, ¹Genentech, Inc., a Member of the Roche Group, South San Francisco, CA, ²Truven Health Analytics, Cambridge, MA, ³Truven Health Analytics, Bethesda, MD, ⁴Division of Pulmonary and Critical Care Medicine, National Jewish Health, Denver, CO
Background/Purpose: Interstitial lung disease (ILD) is commonly associated with rheumatoid arthritis (RA) and can have significant morbidity and mortality. The objective was to calculate the…
Abstract Number: 1456 • 2016 ACR/ARHP Annual Meeting
Identification of a Unique Population of B220hi B-Cells in Inflamed Lymph Nodes (Bin) As a Potential Biomarker of Arthritic Progression in the Tumor Necrosis Factor Transgenic Mouse Model of Rheumatoid Arthritis
Megan Forney¹, Richard Bell², Edward Schwarz³ and Homaira Rahimi⁴, ¹Orthopedics, University of Rochester, Rochester, NY, ²Pathology, University of Rochester, Rochester, NY, ³Orthopedeatrics, University of Rochester, Rochester, NY, ⁴Rheumatology, University of Rochester/Golisano Children's Hosp, Rochester, NY
Background/Purpose: Using the tumor necrosis factor transgenic (TNF-Tg) mouse model of rheumatoid arthritis (RA), we have shown that during progression of knee synovitis, popliteal lymph…
Abstract Number: 1501 • 2016 ACR/ARHP Annual Meeting
The Incidence of Interstial Lung Disease and Malignancies in Veterans with Rheumatoid Arthritis
Katherine Larson¹, Faizah Siddique² and Samya Mohammad¹, ¹Virginia Commonwealth University, Richmond, VA, ²Department of Veterans Affairs, Richmond, VA
Background/Purpose: Rheumatoid arthritis (RA) is a systemic disease with a known association with lymphoma and interstitial lung disease (ILD). ILD is a frequent extraarticular manifestation…
Abstract Number: 2962 • 2015 ACR/ARHP Annual Meeting
Efficacy of Mycophenolate As a Maintenance Therapy Following the Administration of Cyclophosphamide in the Treatment of Interstitial Lung Disease Associated with Systemic Sclerosis
Javier Narváez¹, Helena Borrell Paños², Ivan Castellvi³, Sergi Heredia², Milena Millan³, Susana Herrera⁴, Eulalia Armengol², Josep María LLobet³, Joan Miquel Nolla², María Molina⁵ and Juan José Alegre⁶, ¹Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ³Rheumatology Unit. Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁴Deparment of Pneumology, Hospital Universitario Dr Peset, Valencia, Spain, ⁵Department of Pneumology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁶Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain
Background/Purpose: Treatment with cyclophosphamide (CYC) for 12 months stabilizes lung function parameters and improves respiratory symptoms of patients with systemic sclerosis and diffuse interstitial lung…
Abstract Number: 288 • 2015 ACR/ARHP Annual Meeting
Myositis Associated Interstitial Lung Disease: Clinical Predictors of Failure to Conventional Treatment and Their Response to Tacrolimus
Niharika Sharma¹, Anisha Dua¹, Michael Putman², Rekha Vij³ and Mary Strek³, ¹Rheumatology, The University of Chicago, Chicago, IL, ²Internal Medicine, The University of Chicago, Chicago, IL, ³Pulmonology, The University of Chicago, Chicago, IL
Background/Purpose: Interstitial lung disease (ILD) frequently complicates Polymyositis (PM) and Dermatomyositis (DM) and accounts for significant morbidity and mortality in affected patients. Patients with Myositis…
Abstract Number: 2611 • 2015 ACR/ARHP Annual Meeting
Circulating Monocyte Count Is Significantly Associated with Interstitial Pneumonia in Biologic-Naive Patients with Rheumatoid Arthritis: A Single-Center Prospective Cohort Study (Keio First-Bio Cohort Study)
Keisuke Izumi¹, Misato Hashizume², Yuko Kaneko³, Keiko Yoshimoto¹ and Tsutomu Takeuchi¹, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Product Research Department, Fuji-Gotemba Research Laboratories, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, ³Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose : Interstitial pneumonia (IP) is one of the most critical complications in rheumatoid arthritis (RA). Severe IP is developed in zymosan-treated SKG mice, and…
Abstract Number: 2375 • 2015 ACR/ARHP Annual Meeting
Interstitial Lung Disease in Patients with Anti-PM-Scl Antibody
Hiromichi Tamaki¹, Ruchi Yadav², James Bena³ and Soumya Chatterjee⁴, ¹Department of Rheumatic and Immunologic Diseases, Cleveland Clinic Foundation, Cleveland, OH, ²Diagnostic Radiology, Cleveland Clinic, Cleveland, OH, ³Department of Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH, ⁴Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Patients with anti-PM-Scl antibody (PM-Scl) can present with several different phenotypes: polymyositis (PM), dermtomyositis (DM), systemic sclerosis (SSc), scleromyositis, or sclero-dermatomyositis. Interstitial Lung Disease…
Abstract Number: 2362 • 2015 ACR/ARHP Annual Meeting
Rituximab in the Treatment of Jo-1 Antibody-Associated Antisynthetase Syndrome: Anti-Ro52 Positivity As a Marker for Severity and Treatment Response
Jutta Bauhammer¹, Norbert Blank², Hanns-Martin Lorenz³, Regina Max⁴, Dietmar Krause⁵ and Christoph Fiehn¹, ¹ACURA Centre for Rheumatic Diseases, Baden-Baden, Germany, ²Dept. of Internal Medicine 5, Division of Rheumatology, University of Heidelberg, Heidelberg, Germany, ³Department of Internal Medicine 5, Division of Rheumatology, University of Heidelberg, Heidelberg, Germany, ⁴Dept. of Internal Medicine 5, Division of Rheumatology, University of Heidelberg, Heidelberg, Germany, ⁵Dept. of Medical Informatics, Biometry and Epidemiology, Ruhr University Bochum, Bochum, Germany
Background/Purpose: Rituximab (RIX) has successfully been used for the treatment of severe Jo-1 antibody-associated antisynthetase syndrome (Jo-1 ASS). The aim of this retrospective study was…
Abstract Number: 2360 • 2015 ACR/ARHP Annual Meeting
The Effectiveness of Tacrolimus in Patients with Interstitial Lung Disease Secondary to Autoimmune Disease
Hina Chaudhry¹, Rochella A. Ostrowski² and Rodney Tehrani³, ¹Rheumatolgoy, Loyola University Medical Center, Maywood, IL, ²Rheumatology, Loyola University Medical Center, Maywood, IL, ³Rheum & Immun, Loyola Univ Medical Center, Maywood, IL
Background/Purpose: Interstitial lung disease (ILD) secondary to connective tissue disease (CTD) is most commonly seen in systemic sclerosis followed by polymyositis and dermatomyositis. Anti-synthetase syndrome…
Abstract Number: 1897 • 2015 ACR/ARHP Annual Meeting
Fragmented Qrs Patterns Do Not Correlate with the Degree of Lung and Skin Involvement in Patients with Systemic Sclerosis
Didem Uzunaslan¹, Caner Saygin¹, Mehmet Kostek², Mehmet Ozdemir², Tufan Torun², Servet Altay³ and Gulen Hatemi⁴, ¹Cleveland Clinic, Cleveland, OH, ²Istanbul University, Cerrahpasa Faculty of Medicine, Istanbul, Turkey, ³Edirne Community Hospital, Edirne, Turkey, ⁴Rheumatology, Istanbul University, Cerrahpasa Medical School, Istanbul, Turkey
Background/Purpose: Cardiac involvement is a common subclinical feature of systemic sclerosis (SSc) and results from the widespread fibrosis observed during disease course. Fragmented QRS (fQRS)…
Abstract Number: 1882 • 2015 ACR/ARHP Annual Meeting
The Predictive Value of Pulmonary Function Tests to Diagnose Interstitial Lung Disease in Adults with Early Diffuse Cutaneous Systemic Sclerosis
Elana J. Bernstein¹, Veronica J. Berrocal², Virginia D. Steen³, Victoria K. Shanmugam^4,5, Ami A. Shah⁶, Monique E. Hinchcliff⁷, Faye N. Hant⁸, Jessica K. Gordon⁹, Tracy M. Frech¹⁰, Robyn T. Domsic¹¹, Shervin Assassi¹² and Dinesh Khanna¹³, ¹Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ²Div of Rheumatology, University of Michigan, Ann Arbor, MI, ³Rheumatology, Georgetown University Medical Center, Washington, DC, ⁴Division of Rheumatology, The George Washington University, Washington, DC, ⁵Director, Division of Rheumatology, The George Washington University, Washington, DC, ⁶Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Rheumatology, Northwestern University, Chicago, IL, ⁸Dept of Medicine, Medical University of South Carolina, Charleston, SC, ⁹Rheumatology, Hospital for Special Surgery, New York, NY, ¹⁰Div of Rheumatology, University of Utah, Salt Lake City, UT, ¹¹Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ¹²Rheumatology, University of Texas Medical School at Houston, Houston, TX, ¹³Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in patients with systemic sclerosis (SSc). Patients with diffuse cutaneous systemic sclerosis (dcSSc) have…
Abstract Number: 1590 • 2015 ACR/ARHP Annual Meeting
Rheumatoid Arthritis-Related Interstitial Lung Disease (RA-ILD): Methotrexate and the Extension of Lung Disease Are Associated to Prognosis
Jorge Rojas-Serrano¹, Denisse Herrera-Bringas², Renzo Perez-Dorame³, Mayra Mejia² and Heidegger Mateos-Toledo⁴, ¹Interstitial Lung Diseases Unit, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico, ²Interstitial Lung Diseases Unit, Insituto Nacional de Enfermedades Respiratorias, Mexico, Mexico, ³Intertitial Lung Disease Unit, Instituto Nacional de Enfermedades Respiratorias, Mexico, Mexico, ⁴Interstitial Lung Diseases Unit, Instituto Nacional de Enfermedades Respiratorias, Mexico, Mexico
Background/Purpose:Interstitial lung disease (ILD) is a severe rheumatoid arthritis manifestation with a median survival of 2.6 years. Worst survival has been associated to usual interstitial…